Equillium (NASDAQ:EQ) Lowered to “Strong Sell” Rating by Zacks Research

Posted by Brenda Bartman on Jul 15th, 2026

Zacks Research lowered shares of Equillium (NASDAQ:EQ – Free Report) from a hold rating to a strong sell rating in a research report released on Monday morning,Zacks.com reports.

EQ has been the subject of a number of other reports. Wall Street Zen downgraded shares of Equillium from a “hold” rating to a “sell” rating in a research report on Saturday, June 27th. Oppenheimer began coverage on Equillium in a research note on Thursday, April 23rd. They issued an “outperform” rating and a $7.00 price objective on the stock. Leerink Partners raised Equillium from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $1.00 to $6.00 in a report on Thursday, May 28th. Raymond James Financial reissued a “strong-buy” rating and issued a $7.00 target price on shares of Equillium in a research report on Thursday, May 28th. Finally, Piper Sandler assumed coverage on Equillium in a research report on Monday. They set an “overweight” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Equillium currently has an average rating of “Moderate Buy” and an average price target of $7.57.

View Our Latest Stock Report on EQ

Equillium Price Performance

NASDAQ EQ opened at $2.76 on Monday. The business’s fifty day moving average is $2.69 and its 200-day moving average is $2.06. The stock has a market capitalization of $174.51 million, a price-to-earnings ratio of -8.62 and a beta of 1.77. Equillium has a one year low of $0.34 and a one year high of $3.54.

Equillium (NASDAQ:EQ – Get Free Report) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). Research analysts expect that Equillium will post -0.24 EPS for the current fiscal year.

Insider Transactions at Equillium

In other news, insider Stephen Connelly sold 200,000 shares of Equillium stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $3.16, for a total value of $632,000.00. Following the completion of the transaction, the insider directly owned 793,000 shares in the company, valued at approximately $2,505,880. The trade was a 20.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Penny Tom sold 65,000 shares of Equillium stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $2.95, for a total value of $191,750.00. Following the completion of the transaction, the insider owned 65,000 shares of the company’s stock, valued at approximately $191,750. This trade represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 406,392 shares of company stock valued at $1,224,898 over the last three months. Company insiders own 17.84% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in EQ. Virtu Financial LLC lifted its stake in Equillium by 133.4% in the 3rd quarter. Virtu Financial LLC now owns 23,779 shares of the company’s stock worth $34,000 after purchasing an additional 13,591 shares in the last quarter. Dimensional Fund Advisors LP bought a new position in Equillium in the 1st quarter valued at $31,000. State Street Corp grew its position in shares of Equillium by 13.0% during the 4th quarter. State Street Corp now owns 155,420 shares of the company’s stock valued at $241,000 after purchasing an additional 17,900 shares in the last quarter. Persistent Asset Partners Ltd grew its position in shares of Equillium by 35.0% during the 4th quarter. Persistent Asset Partners Ltd now owns 93,123 shares of the company’s stock valued at $144,000 after purchasing an additional 24,132 shares in the last quarter. Finally, Millennium Management LLC bought a new position in shares of Equillium in the third quarter worth $35,000. Hedge funds and other institutional investors own 27.05% of the company’s stock.

About Equillium

(Get Free Report)

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.